HURA

TuHURA Biosciences, Inc.

2.05 USD

Last updated Sep 5, 11:21 UTC

Yesterday HIGH

$2.16

Yesterday LOW

$2.06

52w HIGH

$3.41

52w LOW

$0.41

EPS

-0.14

PE

-14.64

Next Earnings

Nov 13, 2026

Overview News Government Trades Fundamentals

TuHURA Biosciences, Inc. stock is down -3.3% since 30 days ago. The next earnings date is Nov 13, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 13 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Fri Aug 14, 2026

TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 33.33 percent increase over losses of $(0.21) per share
Benzinga Newsdesk

Mon Jun 15, 2026

TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an
Benzinga Newsdesk

Fri May 15, 2026

TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 13.33 percent increase over losses of $(0.15) per share
Benzinga Newsdesk

Mon Apr 27, 2026

Citizens Initiates Coverage On TuHURA Biosciences with Market Outperform Rating, Announces Price Target of $9

Citizens analyst Silvan Turkcan initiates coverage on TuHURA Biosciences (NASDAQ:HURA) with a Market Outperform rating and announces Price Target of $9.
Benzinga Newsdesk

Wed Apr 22, 2026

TuHURA Biosciences Enters Loan Agreement For Credit Facility Of Up To $50M For Its Pipeline, Ongoing Clinical Trials And General Corporate Expenses

The lender is an affiliate of the Company's largest stockholder, K&V Investment One LLC. Under the terms of the loan agreement, TuHURA will have the ability to draw down monthly on the facility on an as-needed basis
Benzinga Insights

Mon Apr 13, 2026

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Newsdesk

Thu Apr 9, 2026

Watching TuHURA Biosciences; Zacks Small-Cap Research Gives Stock $7 Price Valuation
Benzinga Newsdesk

Wed Apr 8, 2026

TuHURA Biosciences Files $50M At-The-Market Common Stock Offering With H.C. Wainwright As Sales Agent

$50,000,000Common StockWe have entered into an At the Market Offering Agreement (the "Sales Agreement"), dated November 3, 2025, with H.C. Wainwright & Co., LLC (the "Sales Agent"), relating to the shares
Benzinga Insights

Wed Apr 8, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Newsdesk

Wed Apr 1, 2026

TuHURA Biosciences Q4 EPS $(0.13) Beats $(0.14) Estimate

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 3.7 percent. This is a 90.51 percent increase over losses of $(1.37) per share from